Announcement • May 10
Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026 Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026. Announcement • May 08
Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares. Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock. Reported Earnings • May 08
First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025) First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Apr 08
Innospec Inc. to Report Q1, 2026 Results on May 07, 2026 Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026 Announcement • Mar 27
Innospec Inc., Annual General Meeting, May 08, 2026 Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States Reported Earnings • Feb 18
Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024) Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Jan 12
Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026 Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026 Board Change • Jan 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • Nov 08
Dividend of US$0.87 announced Shareholders will receive a dividend of US$0.87. Ex-date: 18th November 2025 Payment date: 26th November 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Reported Earnings • Nov 06
Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024) Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Nov 05
Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025 Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025. Board Change • Oct 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 02
Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025 Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Board Change • Sep 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 06
Second quarter 2025 earnings released: EPS: US$0.94 (vs US$1.25 in 2Q 2024) Second quarter 2025 results: EPS: US$0.94 (down from US$1.25 in 2Q 2024). Revenue: US$439.7m (up 1.1% from 2Q 2024). Net income: US$23.5m (down 25% from 2Q 2024). Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Announcement • Jul 03
Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025 Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 Board Change • Jun 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • May 19
Dividend of US$0.84 announced Shareholders will receive a dividend of US$0.84. Ex-date: 20th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio). However, it is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 59% to bring the payout ratio under control. EPS is expected to grow by 65% over the next year, which is sufficient to bring the dividend into a sustainable range. Board Change • May 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 09
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025 Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025. Buy Or Sell Opportunity • Apr 10
Now 24% overvalued The stock has been flat over the last 90 days, currently trading at US$85.47. The fair value is estimated to be US$68.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 10.0% in 2 years. Earnings are forecast to grow by 345% in the next 2 years. Announcement • Apr 04
Innospec Inc. to Report Q1, 2025 Results on May 08, 2025 Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Announcement • Mar 28
Innospec Inc., Annual General Meeting, May 09, 2025 Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United States Board Change • Mar 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Mar 11
Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares. Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. Recent Insider Transactions • Mar 09
Executive VP & CFO recently sold US$432k worth of stock On the 3rd of March, Ian Cleminson sold around 4k shares on-market at roughly US$101 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.6m. Recent Insider Transactions • Feb 26
COO & Executive VP recently sold US$388k worth of stock On the 21st of February, Philip Boon sold around 4k shares on-market at roughly US$103 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months. New Risk • Feb 19
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 7.2% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.9% net profit margin). Reported Earnings • Feb 19
Full year 2024 earnings released: EPS: US$1.43 (vs US$5.60 in FY 2023) Full year 2024 results: EPS: US$1.43 (down from US$5.60 in FY 2023). Revenue: US$1.85b (down 5.3% from FY 2023). Net income: US$35.6m (down 74% from FY 2023). Profit margin: 1.9% (down from 7.1% in FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom. Board Change • Jan 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Jan 09
Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025 Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025 Declared Dividend • Nov 11
Dividend of US$0.79 announced Shareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover. New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold). Reported Earnings • Nov 06
Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023) Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year. Announcement • Oct 04
Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024 Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024 Recent Insider Transactions • Aug 29
Executive VP & CFO recently sold US$1.1m worth of stock On the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly US$114 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.7m. Reported Earnings • Aug 07
Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023) Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Jul 17
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 9.2% to US$132. The fair value is estimated to be US$107, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year. Announcement • Jul 04
Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024 Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 Announcement • May 11
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024 Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023) First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Announcement • Apr 06
Innospec Inc. to Report Q1, 2024 Results on May 09, 2024 Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Announcement • Apr 03
Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025 On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement. Announcement • Mar 29
Innospec Inc., Annual General Meeting, May 10, 2024 Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters. Recent Insider Transactions • Feb 28
President recently sold US$1.2m worth of stock On the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly US$124 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by US$4.3m. Reported Earnings • Feb 14
Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022) Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom. Board Change • Dec 12
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Dec 12
Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business.
Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023. Board Change • Dec 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022) Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Nov 08
Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023 Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022. Announcement • Aug 13
Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023 Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023 Announcement • Jul 07
Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023 Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023 Upcoming Dividend • May 12
Upcoming dividend of US$0.69 per share at 1.4% yield Eligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%). Reported Earnings • May 05
First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022) First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Announcement • May 05
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023 Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023. Recent Insider Transactions • Mar 04
President recently sold US$2.0m worth of stock On the 28th of February, Patrick Williams sold around 18k shares on-market at roughly US$111 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months. Reported Earnings • Feb 23
Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021) Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Announcement • Jan 11
Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023 Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023